All Updates

All Updates

icon
Filter
Earnings/results
Danimer Scientific reports Q4 2022 results; revenue declines 13.6% YoY
Bio-based Materials
Mar 28, 2023
This week:
Funding
Matr Foods raises EUR 20 million in debt funding to build mycelium meat factory
Plant-based Meat
Today
Last week:
M&A
Platform Science to acquire Trimble's global transportation telematics business units
Truck Industry Tech
Yesterday
Funding
Whatfix raises USD 100 million in Series E funding to expand business
EdTech: Corporate Learning
Yesterday
Product updates
Sky Mavis launches cross-game onboarding solution
Web3 Ecosystem
Sep 14, 2024
Funding
Bicara Therapeutics raises USD 315 million in IPO; plans to develop lead candidate ficerafusp alfa
Precision Medicine
Sep 13, 2024
Partnerships
Massive Bio and Foundation Medicine partner to improve cancer clinical trial enrollment
Precision Medicine
Sep 13, 2024
Partnerships
Moffitt Cancer Center partners with AstraZeneca to advance oncology cell therapies
Cell & Gene Therapy
Sep 13, 2024
Product updates
Quandela launches European quantum computer in North America
Quantum Computing
Sep 13, 2024
Partnerships
IonQ achieves high qubit gate fidelity on barium development platform
Quantum Computing
Sep 13, 2024
Partnerships
Massive Bio and Foundation Medicine partner to improve cancer clinical trial enrollment
Clinical Trial Technology
Sep 13, 2024
Bio-based Materials

Bio-based Materials

Mar 28, 2023

Danimer Scientific reports Q4 2022 results; revenue declines 13.6% YoY

Earnings/results

  • Danimer Scientific reported revenue of USD 15.3 million in Q4 2022, down 13.6% YoY from Q4 2021 and slightly below the consensus estimate of USD 15.6 million. The full-year revenue for FY2022 was down 9.4% YoY at USD 53.2 million, marginally missing the consensus estimate of USD 53.8 million. 

  • The Q4 2022 product revenue dropped (-9.5% YoY) due to a shift in Polyhydroxyalkanoates (PHA)-based resin sales and lower Polylactic acid (PLA)-based resin sales from the cessation of shipments to conflict-affected customers in Ukraine. Services revenue also dropped (-52.5% YoY) during the same period because of the completion of long-term funded R&D projects over the years.

  • In Q4 2022, the adjusted gross profit increased to USD 2.6 million, 5.5x higher than in Q4 2021, driven by a favorable shift in sales mix that helped to offset the impact of reduced revenue. Resultantly, the company's adjusted EBITDA in Q4 2022 improved to a loss of USD 8.6 million compared to a loss of USD 10.2 million in Q4 2021. The company generated a loss of USD 45 million for FY2022, in line with their guidance (between the loss of USD 45 million and the loss of USD 40 million). 

  • Danimer’s guidance for the fiscal year 2023 expects adjusted EBITDA to be between a loss of USD 23 million and a loss of USD 31 million. The improvement is expected to come primarily from revenue growth in PHA-based resins and related benefits of scale from the company's Kentucky manufacturing operations. 

Other key operational highlights:

  • The Kentucky facility has successfully tested and commissioned all major processes and production equipment and expects to achieve an annual production capacity of about 32.5 million pounds of neat PHA, which would result in nearly 65 million pounds of finished resin for shipment to customers. 

  • Danimer has applied for the US Department of Energy (DOE) Title XVII Loan Guarantee Program for its new manufacturing facility in Bainbridge, Georgia. The facility is expected to support around USD 400 million of revenue from PHA-based formulated resins.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.